Investigators from that study revealed that discrepant functional IFNL4 diplotypes non‐redundantly exerted differential impacts on molecular response (MR) in those ROPEG‐treated patients when assessed with changes in JAK2V617F mutant allele burden (AB)8 These data pave ways for potential application of precision medicine in optimizing patient management during IFN therapy for MPN. This evidence concerns the gene IFNL4 and myeloproliferative neoplasm.